Skip Navigation

Randall L. Davis, Ph.D.

Davis

Neuroimmune signaling, Drugs of abuse, Mood and Anxiety disorders

Degree: PhD, Nutrition
Broad Expertise/Interests:
  • Neuroinflammation
  • Pharmacology
  • Drugs of abuse
  • Anxiety and Depression
  • Neuroimmune signaling and Obesity
Equipment/Techniques:
  • In vitro models of neuroinflammation (human astrocytes and microglia)
  • Western blot/Co-IP
  • ELISA
  • RT-PCR
  • Cell Migration
  • Mouse model of neuroinflammation
  • Behavioral analysis (mice); sickness, depression, anxiety
Seeking Collaborators with Skill Sets:
  • Access to human tissues (Brain, blood, or CSF)
  • Interests in HIV dementia, CNS disorders, Mood and Anxiety disorders
Neuroscience Research Interests:

Current:
Identification and characterization of novel anti-inflammatory agents to be used in the treatment of CNS disorders involving neuroinflammation

Understanding the role of neuroimmune signaling in obesity

Future: 
Understanding the impact of prescribed medications (antidepressants, antipsychotics, cART on neuroinflammation and/or neurotoxicity

Funding in the Last Three Years:

OCAS  ,OK-INBRE, TABERC

Publication Highlights:

Davis et al., (2013) Beta-Funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes Neurochem Int 62:478-485.

Davis et al., (2015) The opioid antagonist, beta-funaltrexamine, inhibits NF-kB signaling and chemokine expression in human a and in mice. Eur J Pharmacol 762:193-201.

Davis et al., The opioid antagonis,beta-funaltrexamine, inhibits lipopolysaccharide-induced neuroinflammation and reduces sickness behavior in mice. Physio Behav 173:52-60.

Website: